Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | MME | P08473 | 2/20 | 0.41 |
| ▸ | MDM4 | O15151 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | TLR2 | O60603 | 2/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
| ▸ | CPA1 | P15085 | 1/20 | 0.38 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27146697 | 0.85 | MME (0.49) | MMEACECPA1ACE2 | |
| SCHEMBL27146696 | 0.85 | MME (0.49) | MMEACECPA1ACE2 | |
| SCHEMBL7305789 | 0.81 | IDO1 (0.47) | MDM4TP53IDO1ACE | |
| SCHEMBL29378420 | 0.81 | MDM4 (0.60) | MDM4TP53CASP3TLR2 | |
| SCHEMBL178787 | 0.81 | MDM4 (0.60) | MDM4TP53CASP3TLR2 | |
| SCHEMBL30191581 | 0.81 | MDM4 (0.60) | MDM4TP53CASP3TLR2 | |
| SCHEMBL31675022 | 0.81 | MDM4 (0.60) | MDM4TP53CASP3TLR2 | |
| SCHEMBL29792126 | 0.81 | MDM4 (0.60) | MDM4TP53CASP3TLR2 | |
| SCHEMBL29401430 | 0.81 | MDM4 (0.60) | MDM4TP53CASP3TLR2 | |
| SCHEMBL30353997 | 0.81 | MDM4 (0.60) | MDM4TP53CASP3TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11628221-B2 | Peptide linker and combination for prodrugs activated by prostate-specific antigen | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-04-18 | — | — | US | disclosed |
| US-11129901-B2 | Peptide-linked ester prodrugs activated by prostate-specific antigen | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2021-09-28 | — | — | US | disclosed |
| WO-2018144880-A1 | NEW PEPTIDE-LINKED ESTER PRODRUGS ACTIVATED BY PROSTATE-SPECIFIC ANTIGEN | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2018-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11628221-B2 | Peptide linker and combination for prodrugs activated by prostate-specific antigen | KLK3, DNPEP, FOLH1 | POLB 3191/4885MME 129/4885MDM4 3065/4885 |
| US-11129901-B2 | Peptide-linked ester prodrugs activated by prostate-specific antigen | ACP3, KLK3, DNPEP | POLB 3585/4885MME 77/4885MDM4 2758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.